Based on the aforementioned research findings, we can conclude that specific inflammatory cytokines may play a role in the development of these two subtypes of breast cancer (HER2-positive and HER2-negative), while other inflammatory regulatory factors are more likely to be involved in disease progression. This evidence concerns the gene ERBB2 and breast carcinoma.